CRISPR Therapeutics AG (CRSP)
53.72
-0.34
(-0.63%)
USD |
NASDAQ |
May 31, 16:00
53.75
+0.03
(+0.06%)
After-Hours: 20:00
CRISPR Therapeutics Cash from Operations (Quarterly): 109.75M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 109.75M |
| December 31, 2023 | -96.07M |
| September 30, 2023 | -39.86M |
| June 30, 2023 | -133.24M |
| March 31, 2023 | 8.799M |
| December 31, 2022 | -113.33M |
| September 30, 2022 | -105.22M |
| June 30, 2022 | -141.96M |
| March 31, 2022 | -135.24M |
| December 31, 2021 | -86.04M |
| September 30, 2021 | -81.33M |
| June 30, 2021 | 807.00M |
| March 31, 2021 | -100.66M |
| December 31, 2020 | -81.21M |
| September 30, 2020 | -75.70M |
| June 30, 2020 | -29.28M |
| March 31, 2020 | -52.18M |
| Date | Value |
|---|---|
| December 31, 2019 | 3.376M |
| September 30, 2019 | 133.42M |
| June 30, 2019 | -36.38M |
| March 31, 2019 | -43.74M |
| December 31, 2018 | -28.37M |
| September 30, 2018 | -19.96M |
| June 30, 2018 | -25.22M |
| March 31, 2018 | -22.69M |
| December 31, 2017 | -14.84M |
| September 30, 2017 | -15.87M |
| June 30, 2017 | -15.97M |
| March 31, 2017 | -23.41M |
| December 31, 2016 | -16.97M |
| September 30, 2016 | -12.28M |
| June 30, 2016 | -13.60M |
| March 31, 2016 | -10.01M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-141.96M
Minimum
Jun 2022
807.00M
Maximum
Jun 2021
-12.27M
Average
-78.46M
Median
Cash from Operations (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 1.307B |
| Novartis AG | 2.265B |
| Viking Therapeutics Inc | -6.134M |
| MoonLake Immunotherapeutics | -14.95M |
| Regeneron Pharmaceuticals Inc | 1.512B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -97.80M |
| Cash from Financing (Quarterly) | 305.93M |
| Free Cash Flow | -169.05M |
| Free Cash Flow Per Share (Quarterly) | 1.333 |
| Free Cash Flow Yield | -3.93% |